Abstract: Provided are cDNA, mRNA serving as a reverse transcription template of the cDNA, a protein coded by the mRNA, and a kit and system for evaluating a glioma prognosis. The sequence of the cDNA contains a fragment of SEQ ID NO: 1 or the sequence of the cDNA contains a complementary fragment of the fragment of SEQ ID NO: 1, wherein the fragment of SEQ ID NO: 1 at least contains the sequences of positions 2635-2652, 2623-2640 or 2627-2645 of SEQ ID NO: 1.

Abstract: A kit for evaluating the sensitivity of a patient to an MET inhibitor is provided. The kit includes a first primer pair capable of specifically amplifying a first nucleotide sequence, and/or a first probe capable of being specifically bonded to the first nucleotide sequence, wherein the first nucleotide sequence is as shown in SEQ ID NO: 1, and/or the kit comprises a second primer pair capable of specifically amplifying a second nucleotide sequence, and/or a second probe capable of being specifically bonded to the second nucleotide sequence, wherein the second nucleotide sequence is as shown in SEQ ID NO: 4. The kit provided is capable of screening the patients sensitive to an MET inhibitor.

Abstract: Provided are a kit and system for evaluating glioma and/or gastric adenocarcinoma prognosis. The kit includes a first primer pair capable of specifically amplifying a cDNA fragment of SEQ ID NO: 1, and/or a first probe capable of specifically hybridizing to the cDNA fragment of SEQ ID NO: 1, wherein the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions 4057-4074, positions 4067-4084 or positions 4064-4079 of SEQ ID NO: 1.